Findings based on a systematic literature review of studies reporting the use of ketamine, esketamine for treatment-resistant depression
MONDAY, Aug. 30, 2021 (HealthDay News) — Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.
Breno Souza-Marques, from Faculdade de Medicina da Bahia in Brazil, and colleagues conducted a systematic literature review to identify studies examining the neurocognitive effects of ketamine and esketamine in patients with treatment-resistant major depressive disorder.
Fourteen studies were identified. The researchers found that one study reported impairment of processing speed and verbal memory after ketamine treatment, while five studies reported improvements in processing speed, verbal memory, visual memory, working memory, or cognitive flexibility. No performance changes were found in the esketamine study. Predictors of antidepressant response include lower attention, slower processing speed, and higher working memory. A normalizing tendency after ketamine was seen in brain areas for emotional and reward processing, including the amygdala, insula, and orbitofrontal cortex.
“Ketamine and esketamine do not seem to exert significant deleterious neurocognitive effects in the short or long term in individuals with treatment-resistant depression,” the authors write. “Results suggest neuropsychological functions and brain areas commonly impaired in treatment-resistant depression may especially benefit from subanesthetic ketamine infusions.”
Abstract/Full Text (subscription or payment may be required)
Temporal Interference Stimulation Targeting Prefrontal Cortex May Alleviate Depression Symptoms
CDC: 1 in 10 U.S. Adults Reported GLP-1 Medication Use July to August 2025
Head-to-Head Comparisons Show Three Antidepressants Have Greater Long-Term Efficacy
β3 Agonists Do Not Cut Dementia Risk Versus Anticholinergics in OAB
One-Hour Cognitive Test Provides Meaningful Information Beyond Traditional Memory Screening
CTE Pathology Found in Nearly 75 Percent of Deceased Former NFL Players
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment